controlled clinical trial, the LRC investigators determined that lowering the total and low-density lipoprotein plasma cholesterol concentrations by diet and drug treatment significantly reduced the incidence of CHD. ' In addition, a dose-response relationship was noted.2 Therefore, lowering total and low-density lipoprotein cholesterol concentrations by pharmacologic means has been conclusively demonstrated to prevent CHD.
Currently the bile acid sequestrants cholestyramine and colestipol and the B-complex vitamin niacin are considered the hypocholesterolemic drugs of choice for patients with type II hyperlipoproteinemia. However, up to 30% of patients cannot tolerate cholestyramine because of unpalatability and gastrointestinal side effects.34 Up to 68% of patients treated with cho-THERAPY AND PREVENTION-HYPERLIPIDEMIA lestyramine suffer at least one adverse side effect of the drug2 and the cost of the drug limits its widespread use. At 24 g/day, the cost to the patient for 1 month of cholestyramine treatment in the Washington, D.C., area approaches $170. Therefore, despite the efficacy of therapy with bile acid sequestrants in reducing CHD risk, the search for a well-tolerated, palatable, inexpensive, andc effective hypocholesterolemic drug regimen continues.
Neomycin, when given in low doses orally (2 g/ day), is not absorbed into the circulation,5 but it can reduce total4 6 7 and low-density lipoprotein cholesterol concentrations8 to a degree comparable to that seen with bile acid sequestrants. However, unlike cholestyramine, neomycin is well tolerated. In addition, a 1 month supply of neomycin (taken in doses of 2 g/day) is one-fifth the cost of cholestyramine. Since neomycin appears to reduce low-density lipoprotein cholesterol concentrations by either a reduction in very lowdensity lipoprotein synthesis or a decreased conversion of very low-density lipoprotein to low-density lipoprotein,9 neomycin is a reasonable alternative to colestipol or cholestyramine treatment for patients with type II hyperlipoproteinemia.
Combined treatment with colestipol and niacin has been found to result in an even more striking decrease in total and low-density lipoprotein cholesterol concentrations. 10 We therefore assessed the effect of combined neomycin and niacin therapy in 25 patients with type II hyperlipoproteinemia who were enrolled in a double-blind, randomized, placebo-controlled, crossover clinical trial.
Methods
Patients. Patients with diagnosis of type II hyperlipoproteinia who were followed as outpatients in either the Lipid Metabolism Clinic or the Cardiology Clinic at the National Institutes of Health in Bethesda were invited to participate after the study protocol had been approved by the NHLBI Human Experimentation Committee. Of the 154 type II patients initially identified, 25 lived in the Washington, D.C., area and were willing to participate in the study. After patients had given their consent to participate, they discontinued use of any hypolipidemic medications for 3 months, after which three fasting blood samples for lipoprotein characterization were obtained at monthly intervals. All study patients had low-density lipoprotein cholesterol concentrations in the top tenth percentile for their ages and sexes, as outlined by the LRC." This group included 16 men and nine women who were 25 to 65 years old (mean 49). Patients with secondary hyperlipidemia were excluded through evaluations for levels of total thyroxine, free thyroxine, triiodothyronine, thyroid-stimulating hormone, serum transaminases, alkaline phosphatase, creatinine, BUN, bilirubin, serum protein electrophoresis, fasting glucose, albumin, and total protein in serum and by urinalysis. Eight patients were heterozygous for familial hypercholesterolemia, as determined by family history and the presence of tendon xanthomas.
Nine subjects were hypertensive and were receiving a thiazide diuretic (n = 8) or propranolol (n = 1). No changes in the antihypertensive regimens were made after the beginning of the study. No other drugs known to affect lipid metabolism were taken by the study subjects.
Laboratory determinations. After a 12 to 14 hr fast, study patients in the sitting position had blood drawn in glass tubes with a final EDTA concentration of 0. 01%. Blood samples were immediately placed on ice and plasma was isolated by centrifugation at 40 C. Cholesterol and triglyceride concentrations were determined in whole plasma and lipoprotein subfractions by enzymic assays with a Gilford 3500.12, 13 Plasma aliquots (d -1.006 g/ml) were subjected to 18 to 24 hr, 39,000 rpm ultracentrifugation at 40 C with a 40.3 Ti Beckman rotor. The cholesterol concentration in the 1.006 infranate was substracted from the total plasma cholesterol level to determine the very low-density lipoprotein cholesterol concentration. High-density lipoprotein cholesterol level was determined by quantitating the cholesterol content in the supematant of plasma after dextran-sulfate precipitation (mol wt 50,000; Sochibo, France). 14 The low-density lipoprotein cholesterol concentration was calculated as the difference in cholesterol concentration between the 1.006 g/ml infranate and the level of high-density lipoprotein cholesterol.
Study design. Three months after all hypolipidemic therapy had been stopped, study patients were instructed about the study diet. Three monthly visits later, patients were started on 1 g of neomycin sulfate (Eli Lilly, Indianapolis) twice daily. During the 3 months of treatment with neomycin only, all study subjects returned for monthly visits. Each patient was then randomly assigned by pharmacy personnel to receive, in addition to neomycin, either niacin or an identical niacin placebo formulated at NIH. The final regimen of 1 g three times daily niacin/ niacin placebo was achieved over a 3 week period using either 100 mg niacin tablets or an identical placebo. Patients were instructed to take the medication with meals and avoid hot drinks during the institution of niacin or niacin placebo therapy in order to decrease facial flushing. After taking one of the preparations for 3 months, each patient received the alternate preparation. Neither the patient nor clinic personnel were aware of which preparation the patient was taking. Each month, in addition to measuring fasting lipoprotein concentrations, renal, hepatic, and auditory functions were assessed. Compliance with therapy was assessed by pill counts at the end of each 3 month treatment interval.
Major objectives in dietary counselling and control during the study included weight maintenance to within 5% of initial body weight, cholesterol intake limited to 90 mg/1000 kcal, a polyunsaturated-to-saturated fatty acid ratio of 2:1, and total caloric intake of 15% to 20% protein, 35% to 40% fat, and 40% to 50% carbohydrates. The group of total carbohydrates included starches and sugars in the form of fructose, lactose, and other sugars. Sucrose in table sugar or sugar products and/or ethanol, based on subject preference, were limited to 10% of the total calories. The proposed ethanol allowance ranged from 2/3 to 11/2 oz/day pure ethanol, depending on total calorie requirements. The calorie level established for each subject was based on his or her age, sex, height, weight, and activity level. Diet plans were adjusted as needed throughout the study to reach the dietary objectives.'5 A meal-planning guide in which a food exchange system was used was developed to teach individual diet plans to subjects. A teaching program dealing with topics related to the control of intake of various nutrients was developed and these topics were discussed with each subject during his monthly visit. Every 3 months a 3 day diet record consisting of 2 weekdays and 1 weekend day was kept by each subject before their clinic visit. cholesterol and low-density lipoprotein cholesterol concentrations during the diet-only phase of the study were significantly reduced with neomycin treatment (by 23% and 29%, respectively). Although no additional changes in the plasma lipoprotein concentrations were observed after combination therapy with neomycin and niacin placebo, the addition of niacin to neomycin treatment had a significant impact. The 9% and 12% declines in total and low-density lipoprotein cholesterol concentrations were paralleled by a significant 17% increase in the high-density cholesterol concentration. Therefore, for the entire study group the addition of niacin to the neomycin regimen led to additional significant reductions in total and low-density lipoprotein cholesterol concentrations and an increased high-density lipoprotein cholesterol level.
Since 11 of the 25 study subjects did not tolerate the addition of niacin to the neomycin regimen, the results given for the entire group underestimate the impact of the addition of niacin to the regimen. A more impressive niacin-induced reduction in total and low-density lipoprotein cholesterol concentrations was apparent when patients were grouped as compliers and noncompliers (table 2) . This compliance classification was made at the conclusion of the study, but independently of the lipid data analysis and based on the niacin pill counts. "Compliers" consumed more than 85% of their prescribed niacin doses, whereas "noncompliers" ingested less than 50% of prescribed doses. Both groups ingested more than 85% of their prescribed neomycin doses. The separation of study subjects based on medication compliance is reflected in the differences in lipid concentrations during the niacin placebo and niacin treatment periods. No During the double-blind, placebo-controlled crossover study of neomycin conducted previously in these same patients,8 a significant residual effect of neomycin on the plasma lipoproteins was observed in study subjects receiving neomycin first. The total and lowdensity lipoprotein cholesterol levels during the 3 month placebo period were still reduced 7% to 12% from baseline. The effect of order in which the two treatments were received (niacin and niacin placebo) was therefore assessed. Evaluation of the effect of treatment on the lipoprotein concentrations for the total group, the compliers, and the noncompliers indicated that no residual or carryover effect was present with niacin treatment. Therefore, unlike the previous neomycin study, there is no underestimation of these niacin-induced effects.
These additional lipid and lipoprotein changes with neomycin/niacin treatment could not be explained by dietary changes during the study. Daily total caloric intake, polyunsaturated-to-saturated fatty acid ratio, daily cholesterol intake and ethanol intake, and the percent of calories taken as protein, carbohydrate, and fat did not change between periods. Paired t tests comparing these variables between treatment periods disclosed no significant differences. Furthermore, an analysis of covariance carried out with the above variables plus neomycin treatment as a covariate demonstrated that neomycin/niacin treatment was independently correlated with these changes in total cholesterol (p = .0001), low-density lipoprotein cholesterol (p = .0019), and high-density lipoprotein cholesterol concentrations (p < .001). Values are mean ± SD for the entire study group. Alk phos = alkaline phosphatase; bili = bilirubin.
AStatistically significant difference from neomycin only (p < .05).
BStatistically significant difference from neomycin + placebo (p < .05).
paralleled by alterations in the clinical side effects experienced by our patients (table 4) . As previously reported, neomycin induced mild nausea in 1 1% of treated patients, but this was relieved by taking the medication with meals. Niacin treatment, on the other hand, led to an increased incidence of abdominal pain, flushing, pruritus, rash, and dry eyes. These side effects were noted by both compliers and noncompliers. However, the noncompliers experienced significantly more headaches, nausea, and dry eyes during the niacin period than did compliers. The severity of skin flushing as well as nausea was the cause for discontinuing or limiting the niacin dose in the noncompliers. One patient developed signs and symptoms of hepatitis and another developed symptomatic hypotension during niacin therapy; niacin therapy was stopped in these patients. By 1 month after therapy was stopped, all these signs and symptoms had totally resolved. No glycosuria, frank diabetes, peptic ulcer disease, or acute gouty attacks developed over the course of the study. Although no serious or irreversible sequelae to niacin therapy developed, the annoying side effects contrasted sharply with the very well-tolerated neomycin. TABLE 4 Finally, no ototoxicity developed in any study subject. Puretone threshold, speech discrimination, speech-reception threshold, ipsilateral noise discrimination, and acoustic reflex threshold were unaffected during the study. All 25 of these patients have subsequently been maintained on 2 g/day neomycin for 12 to 30 months without any sign of ototoxicity. Therefore, sensitive, prospective evaluation indicates that prolonged use of neomycin has no adverse otologic effects at this dosage.
Discussion
The recent results of the LRC Coronary Primary Prevention Trial," 2 as well as the NHLBI Intervention Study, '9 20 indicate that diet and drug intervention is useful in patients with increased concentrations of lowdensity lipoprotein cholesterol. Treatment not only retards the development of coronary atherosclerosis, 19 20 it also prevents myocardial infarction and death.'1 2 Therefore, the questions involved in clinical practice shift from "whether to treat" to "how best to treat."
A variety of medications including cholesltyramine, colestipol, niacin, probucol, clofibrate, and gemfibro- Neomycin is a nonabsorbable aminoglycoside antibiotic that has limited use in the treatment of infection. However, when taken in small doses orally, it lowers total and low-density lipoprotein cholesterol concentrations in type II hyperlipoproteinemic patients.4 6 8 The effect of neomycin on the plasma lipoproteins is qualitatively and quantitatively similar to that achieved with the bile acid sequestrants cholestyramine and colestipol.8 Since little, if any, ototoxicity or nephrotoxicity has been reported in patients free of underlying intestinal, renal, or hepatic disease when the low dose of 2 g/day is used, neomycin appears as a promising addition in the treatment of the hyperlipoproteinemias. The present findings of respective reductions of 23% and 29% in total and low-density lipoprotein cholesterol concentrations are similar to results of our previous study.8 Moreover, all these patients have been treated with neomycin for at least a full year and some as long as 30 months without any evidence of toxicity. Therefore, neomycin is as safe and effective in the treatment of increased low-density lipoprotein cholesterol concentration as a variety of other drugs. Moreover, use of neomycin has the advantages that it may be given twice a day in tablet form, that there are no adverse side effects that compromise compliance, and that it is low cost (roughly 20% that of cholestyramine).
Since neomycin appears to act via inhibition of intestinal cholesterol absorption,9 combination with niacin would be anticipated to provide complementary modes of action in the reduction of plasma lipid concentrations. In the patients compliant to both neomycin and niacin treatment. the reductions in total and lowdensity lipoprotein cholesterol concentrations were 36% and 45%, respectively. In addition, the highdensity lipoprotein cholesterol concentration increased by 32%. In a total of 13 
